5,6,7,8-tetrahydro-1,7-naphthyridin-2-ol | 1196154-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5,6,7,8-tetrahydro-1,7-naphthyridin-2-ol
• 英文别名: 5,6,7,8-Tetrahydro-1,7-naphthyridin-2(1H)-one；5,6,7,8-tetrahydro-1H-1,7-naphthyridin-2-one
• CAS: 1196154-84-3
• 化学式: C₈H₁₀N₂O
• 分子量: 150.18
• InChiKey: OZLBNELUODRSQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  450.8±37.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6,7,8-tetrahydro-1,7-naphthyridin-2-ol 在 cyanomethyl tributylphosphorane 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 19.0h， 生成 2-[(5-methoxypyridin-2-yl)methoxy]-7-(6-methoxypyridine-3-carbonyl)-5,6,7,8-tetrahydro-1,7-naphthyridine
  参考文献：
  名称：

  [EN] COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN
  [FR] COMPOSÉS ET SONDES POUR L'IMAGERIE DE LA PROTÉINE HUNTINGTINE

  摘要：

  本文提供了某些具有化学式（I）的化合物和成像剂，用于检测与蛋白聚集相关的病症或疾病，以及这些化合物的组成物和使用方法。

  公开号：

  WO2021127265A1

文献信息

• [EN] 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS<br/>[FR] ANALOGUES DE 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE
  申请人：ZENO ROYALTIES & MILESTONES LLC

  公开号：WO2019028008A1

  公开（公告）日：2019-02-07

  Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

  本文提供了式（I）的化合物。这些化合物以及其药学上可接受的盐和组合物对于治疗疾病或症状是有用的，包括那些以细胞过度增殖为特征的病症，比如乳腺癌。
• Pyrid-2-one derivatives and methods of use
  申请人：——

  公开号：US20040147561A1

  公开（公告）日：2004-07-29

  Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疾病，如细胞增殖或凋亡介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及中风、癌症等疾病和其他疾病或病况的药物组合物和方法。该主题发明还涉及制备此类化合物的方法，以及在这些过程中有用的中间体。
• NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：US20190161501A1

  公开（公告）日：2019-05-30

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X 1 is each independently CR 4a R 4b , X 2 is each independently CR 4c R 4d , Y 1 and Y 2 are each independently a carbon atom or a nitrogen atom, L is —N(R 6 )—C(═O)— or the like, W is cyclyl or the like, R 2 and R 3 are each independently substituted or unsubstituted alkyl or the like, R 1a , R 1b , R 4a to R 4d , and R 6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供具有D3受体拮抗活性的新化合物。一种由以下式（I）表示的化合物：其中环A是杂环，X1分别是CR4aR4b，X2分别是CR4cR4d，Y1和Y2分别是碳原子或氮原子，L是—N(R6)—C(═O)—或类似物，W是环烷基或类似物，R2和R3分别是取代或未取代的烷基或类似物，R1a、R1b、R4a到R4d和R6分别是氢原子或类似物，p为1或2，q是1到3的整数，n是1到4的整数，s是0到4的整数，或其药学上可接受的盐。
• [EN] HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021058416A1

  公开（公告）日：2021-04-01

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式(I)的新杂环化合物，其中A、L、Q、U、V、W、X、Z、m、n以及R1到R4如本文所述，包括这些化合物的组合物，制造这些化合物的过程以及使用这些化合物的方法。
• Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
  申请人：Shionogi & Co., Ltd.

  公开号：US10870660B2

  公开（公告）日：2020-12-22

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(═O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供了具有 D3 受体拮抗活性的新型化合物。 由式（I）代表的化合物： 其中 环 A 是杂环，X1 各自独立地为 CR4aR4b，X2 各自独立地为 CR4cR4d，Y1 和 Y2 各自独立地为碳原子或氮原子、 L是-N(R6)-C(═O)-或类似物，W是环烷基或类似物，R2和R3各自独立地是取代或未取代的烷基或类似物，R1a、R1b、R4a至R4d和R6各自独立地是氢原子或类似物、 p 是 1 或 2，q 是 1 至 3 的整数，n 是 1 至 4 的整数，s 是 0 至 4 的整数、 或其药学上可接受的盐。